Acquisition · Shareholders have voted
Bio-techne Corp acquisition by Merck KGaA, Darmstadt, Germany: what happens to stock options and RSUs
Merck KGaA, Darmstadt, Germany, is buying Bio-Techne for $73.00 per share in cash; shareholders voted on September 23, 2026. Vested options are paid the difference between $73.00 and their exercise price. Check the proxy for unvested options and RSUs.
- Buyer
- Merck KGaA, Darmstadt, Germany
- What holders receive
- $73.00 per share in cash
- Agreement signed
- June 25, 2026
- Shareholder vote
- September 23, 2026
- Expected closing
- Not stated in the filing
How equity awards are treated
| Stock options | Vested options cashed out for the spread over $73.00; see the proxy for unvested options |
|---|---|
| Options priced above the deal | cancelled for no payment (likely) |
| Unvested RSUs | converted, keep vesting on original schedule (likely) |
| Performance awards (PSUs) | mentioned; terms vary |
Estimate your payout at $73.00 per share
Options pay the spread between the deal price and the exercise price; options priced at or above $73.00 usually pay nothing. Whether unvested awards pay now or later depends on the treatment above. Before taxes.
What this means for your taxes
- Shares you own outright are sold for cash at closing. That is a taxable sale: the gain over your cost basis is a capital gain, long-term if you have held the shares more than a year at closing. For shares from vested RSUs, your basis is generally the value already taxed at vesting (it was on your W-2).
- Options and RSUs paid in cash run through payroll as wages: income tax plus Social Security and Medicare. Employers usually withhold federal income tax at a flat 22%, or 37% on supplemental wages above $1 million in the calendar year (IRS Publication 15). If your top bracket is higher than 22%, withholding can fall short and you may owe more when you file; an estimated payment avoids a surprise.
- Incentive stock options that are cancelled for cash generally do not get ISO treatment: the payment is taxed like wages, the same as non-qualified options.
- ESPP shares sold in the deal within 2 years of the offering date or 1 year of purchase are a disqualifying disposition: part of the gain is taxed as ordinary income.
General rules, not advice for your situation. Your award agreement and the merger agreement control. Full guide: stock options and RSUs in an acquisition →
Get updates on the Bio-techne Corp deal
We'll email you when shareholders vote, when the deal closes, and if terms change. Your payout estimate is saved with your alerts.
One email per alert. Unsubscribe any time. We never sell your address.
Holding a large position in one stock?
Get our checklist of the ways people diversify a concentrated position (staged sales under a 10b5-1 plan, exchange funds, collars, gifting appreciated shares) and the tax trade-off of each. One email, plus alerts for this company.
One email per alert. Unsubscribe any time. We never sell your address.
Source
From the company's SEC filing: DEFM14A (accession 0001140361-26-033911). Last checked against the filing on November 19, 2026. Found an error? Corrections are made the same day; see how we check.
Questions
What will Bio-techne Corp shareholders receive?
Under the merger agreement, holders receive $73.00 per share in cash.
What happens to Bio-techne Corp stock options and RSUs?
Stock options: Vested options cashed out for the spread over $73.00; see the proxy for unvested options; Options priced above the deal: cancelled for no payment (likely); Unvested RSUs: converted, keep vesting on original schedule (likely); Performance awards (PSUs): mentioned; terms vary
When will the deal close?
The filing does not give a specific closing date; closing depends on approvals.